Opinion|Videos|January 10, 2025
Revumenib’s FDA Approval and Clinical Implications
Panelists discuss the FDA approval of revumenib for relapsed/refractory acute leukemia (R/R AML) with KMT2A translocation, reviewing the eligible patient population and the mechanism of action of this menin inhibitor, while exploring key findings from the AUGMENT-101 trial and how this approval may impact treatment approaches in both the R/R and broader AML settings.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Provide details of the FDA approval on November 15, 2024, for revumenib in R/R acute leukemia with KMT2A translocation.
- Briefly review the population, and which patients can be treated with this new therapy.
- Briefly discuss the mechanism of action of this menin inhibitor, revumenib.
- Briefly comment on key takeaways from AUGMENT-101 efficacy and safety data that led to FDA approval
- What aspects of revumenib’s efficacy and safety profile stand out compared with other approved agents in AML?
- How does this FDA approval impact your treatment approach for AML overall (including R/R setting)?
Advertisement
Related to this article
A pilot study represents a milestone toward testing a faster, more powerful, and potentially less-toxic form of radiation therapy for cancer treatment.
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
UTRxMYCN M1-14 received orphan drug status for soft tissue sarcoma and RPDD for rhabdomyosarcoma.
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Plinabulin Plus Docetaxel in Post-ICI Non-Squamous NSCLC
2
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
3
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
4
Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape
5